Engineered immune cells are moving from the lab bench to reprogramming the body from within

Engineered immune cells, most famously CAR T cells, have transformed treatment for some blood cancers. Yet complex manufacturing, high cost, safety risks, and limited success against solid tumors keep them out of reach for many patients. For a longevity audience, the technology also points toward tools that might one day target age-related chronic inflammation and immune dysfunction.

This narrative review compares the main approaches to immune cell engineering. It examines delivery systems (viral vectors, lipid nanoparticles, polymer-based carriers), gene editing and expression tools (mRNA platforms, CRISPR), and the design of synthetic regulatory elements that control cell behavior.

According to the abstract, CAR concepts are expanding beyond T cells to macrophages, natural killer cells, and dendritic cells. Therapeutic targets are broadening from hematologic malignancies to solid tumors, autoimmune disease, infectious disease, and chronic inflammatory disorders. The review highlights a shift from ex vivo cell manipulation toward in vivo reprogramming, which may address manufacturing bottlenecks and improve clinical accessibility. It also describes growing use of artificial intelligence to guide rational design of vectors, CAR structures, and signaling networks.

The implications are that future cell therapies could become more off-the-shelf, more versatile across cell types, and applicable to a wider range of diseases. Rational and AI-assisted design may accelerate optimization.

Caveats are substantial. The authors acknowledge unresolved challenges in safety, long-term persistence of engineered cells, and microenvironmental barriers that blunt efficacy, particularly in solid tumors. As a review assessed from its abstract alone, it does not present new clinical data, and the degree of evidence for each approach cannot be judged here.